Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $13.32, but opened at $12.30. Telix Pharmaceuticals shares last traded at $12.18, with a volume of 6,914 shares traded.
Wall Street Analyst Weigh In
TLX has been the topic of several recent analyst reports. Wedbush reiterated an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th. William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. Finally, HC Wainwright started coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They set a "buy" rating and a $23.00 target price for the company.
Read Our Latest Report on Telix Pharmaceuticals
Telix Pharmaceuticals Stock Performance
The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. The company has a 50 day simple moving average of $15.80 and a 200-day simple moving average of $16.82.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Private Advisor Group LLC acquired a new position in Telix Pharmaceuticals during the 1st quarter valued at about $170,000. Pier Capital LLC bought a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $3,037,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $297,000. Blair William & Co. IL acquired a new position in shares of Telix Pharmaceuticals during the second quarter worth approximately $217,000. Finally, ABC Arbitrage SA bought a new position in Telix Pharmaceuticals in the 1st quarter worth approximately $451,000.
Telix Pharmaceuticals Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
